» Articles » PMID: 18393320

Loss of Orphan Receptor Small Heterodimer Partner Sensitizes Mice to Liver Injury from Obstructive Cholestasis

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2008 Apr 9
PMID 18393320
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: The orphan nuclear hormone receptor small heterodimer partner (SHP) regulates the expression of several genes involved in bile acid homeostasis in the liver. Because bile acid toxicity is a major source of liver injury in cholestatic disease, we explored the role of SHP in liver damage induced by common bile duct ligation (BDL). Shp(-/-) mice show increased sensitivity in this model of acute obstructive cholestasis, with greater numbers of bile infarcts and higher mortality than wild-type C57BL/6 mice. This increased sensitivity could not be accounted for by differences in expression of bile acid homeostatic genes 2 or 5 days after BDL. Instead, higher basal expression of such genes, including the key biosynthetic enzyme cholesterol 7alpha hydroxylase (Cyp7A1) and the bile salt export pump, is associated with both an increase in bile flow prior to BDL and an increase in acute liver damage at only 1.5 hours after BDL in Shp(-/-) mice, as shown by bile infarcts. At 3 hours, Cyp7A1 expression still remained elevated in Shp(-/-) with respect to wild-type mice, and the hepatic and serum bile acid levels and total hepatobiliary bile acid pool were significantly increased. The increased sensitivity of mice lacking SHP contrasts with the decreased sensitivity of mice lacking the farnesoid X receptor (FXR; nuclear receptor subfamily 1, group H, member 4) to BDL, which has been associated with decreased intraductal pressure and fewer bile infarcts.

Conclusion: We propose that differences in acute responses to BDL, particularly the early formation of bile infarcts, are a primary determinant of the differences in longer term sensitivity of the Fxr(-/-) and Shp(-/-) mice to acute obstructive cholestasis.

Citing Articles

Deletion of hepatic small heterodimer partner ameliorates development of nonalcoholic steatohepatitis in mice.

Lee Y, Park J, Lee M, Mifflin R, Xu Y, Novak R J Lipid Res. 2023; 64(11):100454.

PMID: 37827334 PMC: 10665942. DOI: 10.1016/j.jlr.2023.100454.


Influence of ursodeoxycholic acid on blood glucose, insulin and GLP-1 in rats with liver fibrosis induced by bile duct ligation.

Bai X, Du W, Xing H, Yang G, Bai R Diabetol Metab Syndr. 2023; 15(1):18.

PMID: 36788623 PMC: 9930340. DOI: 10.1186/s13098-023-00989-z.


Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling.

Di Ciaula A, Bonfrate L, Baj J, Khalil M, Garruti G, Stellaard F Nutrients. 2022; 14(23).

PMID: 36500979 PMC: 9738051. DOI: 10.3390/nu14234950.


Discovery of farnesoid X receptor and its role in bile acid metabolism.

Chiang J, Ferrell J Mol Cell Endocrinol. 2022; 548:111618.

PMID: 35283218 PMC: 9038687. DOI: 10.1016/j.mce.2022.111618.


Rebuttal to: The Benevolent Bile: Bile Acids as Stimulants of Liver Regeneration.

Zhou W, Anakk S Cell Mol Gastroenterol Hepatol. 2022; 13(5):1481-1482.

PMID: 35144029 PMC: 9043299. DOI: 10.1016/j.jcmgh.2022.02.002.